Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle

RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...

Novo Nordisk: Wegovy Pill Is Not A Game Changer

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...

The Biggest Problem for Housing Affordability Isn’t Interest Rates

If the Trump administration is serious about housing affordability, it needs to toss out some rules, Satish Mansukhani writes ...

Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026

Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens ...

NVIDIA Kicks Off the Next Generation of AI With Rubin — Six New Chips, One Incredible AI Supercomputer

Extreme Codesign Across NVIDIA Vera CPU, Rubin GPU, NVLink 6 Switch, ConnectX-9 SuperNIC, BlueField-4 DPU and Spectrum-6 ...